Navigation Links
SNM applauds FDA's decision to approve Zevalin
Date:9/10/2009

RESTON, Va.SNM applauds the U.S. Food and Drug Administration's (FDA) recent decision to approve the radioimmunotherapy (RIT) drug, Zevalin, as a front-line treatment of non-Hodgkin's lymphoma (NHL).

"This is welcome news for patients with non-Hodgkin's lymphoma," said Michael M. Graham, M.D., Ph.D., president of SNM and director of nuclear medicine at the University of Iowa Carver College of Medicine. "We've known for some time that RIT works extremely well for many NHL patients. With the FDA's approval, more patients can take advantage of this promising treatment sooner rather than later, giving them more hope for a brighter future."

This is the first time that the drug has been approved as an effective treatment option at the time of onset of lymphoma. Previously, Zevalin was approved only to treat lymphoma after a relapse, or after all conventional therapies failed. Now, patients with NHL can reap the same benefits earlier on in the disease, before it progresses to a more serious stage.

Non-Hodgkin's lymphomaone of the two main types of lymphomahas many different forms and is the fifth most common cancer in the United States. When lymphoma is first diagnosed, treatment choices depend on the cell type, extent of disease and rate of progression. New and emerging molecular imaging therapies, such as RIT, continue to provide major breakthroughs for patients with NHL by allowing tailored treatments at the molecular level. RIT is a more highly targeted therapy than traditional treatments because molecular imaging techniques and therapies can pinpoint the exact location of disease and deliver a tumor-killing dose of a radioactive substance directly to the cancer cells while sparing healthy cells.

"New developments in molecular imaging technologies are dramatically improving the ways in which lymphoma is diagnosed and treated," says Peter S. Conti, M.D., Ph.D., professor of radiology, clinical pharmacy and biomedical engineering at the University of Southern California's Keck School of Medicine. "Research in molecular imaging is also contributing to our understanding of lymphoma and helping to direct more effective care of patients with the disease."


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. National Alliance for Hispanic Health Applauds President Obamas Efforts to Achieve Meaningful Health Care Reform in 2009
2. The American Heart Association Applauds Recommendations in New Childhood Obesity Report
3. HIMSS Electronic Health Record Association Applauds Federal Support of EHR Implementation for Hospitals and Physician Practices
4. NABP Applauds LegitScript and KnujOn for Spotlighting Exploitation of Internet Ad Programs by Rogue Internet Drug Outlets
5. Americans United for Life Applauds Decision Protecting Women From Dangers of RU-486
6. The Lupus Foundation of America Applauds New Legislation that Caps Out-of-Pocket Drug Costs
7. National Alliance for Hispanic Health Applauds Confirmation of Sonia Sotomayor as the Nations 111th Supreme Court Justice
8. The Scleroderma Foundation Applauds Introduction of First Bill in the Senate Promoting Research and Awareness of Scleroderma
9. GMA Applauds U.S. House for Passage of Landmark Food Safety Bill
10. Partnership Applauds Obamas No Cost-Sharing Protections for Preventive Services
11. APHA Applauds Congressional Action on Health Reform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... February 19, 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals ... easily reveal any logo with a glitch reveal in just a few clicks of a ... and animation of each preset. Use these presets to add a uniquely animated logo to ...
(Date:2/19/2017)... (PRWEB) , ... February 19, 2017 , ... ... solutions for connected home healthcare, will join forces with Healthwise ® at ... education. Healthwise, the industry leader in evidence-based health education, technology and services, ...
(Date:2/18/2017)... Waltham, Massachusetts (PRWEB) , ... February 17, 2017 ... ... be the leading source of disruptive innovation in the industry, according to the ... Insights Reports are based on surveys of the NEJM Catalyst Insights Council, a ...
(Date:2/18/2017)... ... February 17, 2017 , ... CONTACT:, Glenn Vallecillos, MD, FACS, ... surgeon Dr. Glenn Vallecillos experiments SculpSure, the hot, new, aesthetic, non-surgical ... has been centered around that idea that to achieve ones desired results a ...
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume 2 features ... ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. Great for ... and choose from hand-crafted trend-setting designs with smooth animations that will add stylistic ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, Inc. ... company focused on the development and commercialization of ... pain, announced that Vincent J. Angotti ... member of the company,s board of directors, effective ... two decades of experience leading executive and commercial ...
(Date:2/16/2017)... and SCOTTSDALE, Ariz. , Feb. 16, 2017 ... Information Exchange (HIE), announced today it is partnering with Orion ... HIE contains 98% of all Maine ... Maine hospitals and over 500 ambulatory care sites. ... HealthInfoNet plans to deploy Orion Health,s Amadeus , a ...
(Date:2/16/2017)... -- Die Stärkung der regulatorischen Infrastruktur ... Medizinproduktebranche oberste Priorität. Während die UDI-Implementierung in Nordamerika ... unmittelbar anstehende regulatorische Änderungen auf dem europäischen Markt ... ... Aufsichtsbehörden, Hersteller von Medizintechnik, Gesundheitsversorger und ...
Breaking Medicine Technology: